Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, Pfeiffer A, Muellner M, Tauber E, Ramsauer K. Reisinger EC, et al. Among authors: firbas c. Lancet. 2019 Dec 22;392(10165):2718-2727. doi: 10.1016/S0140-6736(18)32488-7. Epub 2018 Nov 5. Lancet. 2019. PMID: 30409443 Clinical Trial.
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A. Tauber E, et al. Among authors: firbas c. J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. J Infect Dis. 2008. PMID: 18588481 Clinical Trial.
A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. Westritschnig K, et al. Among authors: firbas c. Hum Vaccin Immunother. 2014;10(1):170-83. doi: 10.4161/hv.26565. Epub 2013 Sep 24. Hum Vaccin Immunother. 2014. PMID: 24064511 Free PMC article. Clinical Trial.
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
Ramsauer K, Schwameis M, Firbas C, Müllner M, Putnak RJ, Thomas SJ, Desprès P, Tauber E, Jilma B, Tangy F. Ramsauer K, et al. Among authors: firbas c. Lancet Infect Dis. 2015 May;15(5):519-27. doi: 10.1016/S1473-3099(15)70043-5. Epub 2015 Mar 2. Lancet Infect Dis. 2015. PMID: 25739878 Clinical Trial.
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial.
Schwameis M, Roppenser B, Firbas C, Gruener CS, Model N, Stich N, Roetzer A, Buchtele N, Jilma B, Eibl MM. Schwameis M, et al. Among authors: firbas c. Lancet Infect Dis. 2016 Sep;16(9):1036-1044. doi: 10.1016/S1473-3099(16)30115-3. Epub 2016 Jun 10. Lancet Infect Dis. 2016. PMID: 27296693 Clinical Trial.
Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study.
Sieghart D, Hana CA, Haslacher H, Perkmann T, Heinz LX, Fedrizzi C, Anderle K, Wiedermann U, Condur I, Drapalik S, Steinbrecher H, Mrak D, Mucher P, Hasenoehrl T, Zrdavkovic A, Wagner B, Palma S, Jordakieva G, Jorda A, Firbas C, Wagner A, Haiden N, Bergmann F, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. Among authors: firbas c. Clin Infect Dis. 2023 Mar 4;76(5):816-823. doi: 10.1093/cid/ciac840. Clin Infect Dis. 2023. PMID: 36328594
Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
Sieghart D, Hana CA, Dürrschmid C, Heinz LX, Haslacher H, Zlesak M, Piccini G, Manenti A, Montomoli E, Jorda A, Fedrizzi C, Hasenoehrl T, Zdravkovic A, Anderle K, Wiedermann U, Drapalik S, Steinbrecher H, Bergmann F, Firbas C, Jordakieva G, Wagner B, Leonardi M, Pierleoni G, Ballini M, Benincasa L, Marchi S, Trombetta C, Perkmann T, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. Among authors: firbas c. J Clin Virol. 2024 Aug;173:105661. doi: 10.1016/j.jcv.2024.105661. Epub 2024 Feb 28. J Clin Virol. 2024. PMID: 38503118 Clinical Trial.
56 results